WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating ...

Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth ...

Unfortunately, there still remains challenging in the treatment of microcystic LMs given their size. We introduce the intralesional laser thermolysis (ILT) technique, a novel enhancement technique for ...

is currently in development for microcystic lymphatic malformations and cutaneous venous malformations. The firm believes the key differentiator of QTORIN rapamycin lies in its unique formulation ...

Kaupinen said the transactions will enable Palvella to accelerate late-stage development of its lead drug candidate, Qtorin rapamycin, as a potential treatment for microcystic lymphatic ...

Kaupinen said the transactions will enable Palvella to accelerate late-stage development of its lead drug candidate, Qtorin rapamycin, as a potential treatment for microcystic lymphatic ...

Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORIN™ rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further ...

A 71-year-old woman presented with a firm flesh-colored plaque with overlying whitish discoloration that had been present on her left cheek for at least 15 years (Figure 1). The lesion measured 1 ...